NC
TARS icon

nVerses Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

nVerses Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-700
Closed -$23K – 797
2024
Q3 		$23K Buy
+700
New +$19.7K 0.01% 787
2024
Q2 		– Sell
-1,900
Closed -$69.1K – 1205
2024
Q1 		$69.1K Buy
+1,900
New +$55.9K 0.17% 226

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

nVerses Capital's TARS Position: Q4 2024 in Review

nVerses Capital sold out of Tarsus Pharmaceuticals (TARS) in Q4 2024, closing a stake of 700 shares — an estimated $23K sold.

nVerses Capital first reported a position in TARS in Q1 2024 and held it in 2 quarters. The position peaked at $69.1K in Q1 2024. 195 funds tracked by Wall St. Rank hold TARS as of Q4 2024.

  • nVerses Capital reported no remaining Tarsus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 700 Tarsus Pharmaceuticals shares in Q4 2024, an estimated $23K.
  • nVerses Capital first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Tarsus Pharmaceuticals position peaked at $69.1K in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.